Please login to the form below
ramucirumab
This page shows the latest ramucirumab news and features for those working in and with pharma, biotech and healthcare.
Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC
The Oncologic Drugs Advisory Committee of the FDA reviewed the safety and efficacy data from the phase 3 RELAY trial of Cyramza (ramucirumab) in patients with EGFR-positive NSCLC, which is
Latest news
-
Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial
It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and recently launched Cyramza (ramucirumab), but was a late entrant into the cancer immunotherapy sector, and the Armo deal is viewed as a
-
Lilly scores FDA okay for Cyramza in liver cancer
The FDA approval is for Cyramza (ramucirumab) – a VEGF receptor 2 antagonist – as a second-line treatment after Bayer’s multikinase inhibitor Nexavar (sorafenib), often used as a first-line targeted
-
EMA says Lilly’s Lartruvo should not be prescribed
along with other newer cancer drugs such as Cyramza (ramucirumab).
-
Home-grown colorectal cancer drug approved in China
treated previously with intravenous VEGF drugs, such as Roche’s Avastin (bevacizumab) and Lilly’s Cyramza (ramucirumab).
-
Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline
It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and recently launched Cyramza (ramucirumab).
More from news
Approximately 9 fully matching, plus 32 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Roche’s Ocrevus boasts positive long-term data in MS
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
bmore group
OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
